1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1629
  6. Examiner Seitz

Examiner Seitz Anthony J

1629-SEITZ-ANTHONY-J

Employment Information

Art Unit:1629 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
546 — Organic compounds -- part of the class 532-570 series
544 — Organic compounds -- part of the class 532-570 series
548 — Organic compounds -- part of the class 532-570 series
549 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
Phone:(703) 756-4657
Email:None
Location:None
Title:Pat Examnr Gen Chem
Service:3 years
Grade:GS-11

Grant Rate and Difficulty Ranking

95
3-Year Grant rate: 13% over 38 cases
Difficulty: Extremely Hard
Difficulty Percentile: 95th

With Examiner Seitz, you have a 13% chance of getting an issued patent by 3 years after the first office action. Examiner Seitz is an extremely hard examiner and in the 95th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Seitz, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1629

Examiner Seitz's grant rate is lower than that of Art Unit 1629 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Seitz 1.6
Art Unit 1629 1.4

Interview Benefit

Grant Rate without Interview

Examiner Seitz has granted 4 of 35 cases without any applicant-requested interviews for a grant rate of 11%.

Grant Rate with Interview

Examiner Seitz has granted 1 of 3 cases with at least one applicant-requested interview for a grant rate of 33%.

Interview Benefit

With Examiner Seitz, conducting an interview increases your chance of getting a patent granted by 200%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18016164 Pyrazolopyrimidine Compound Used As Atr Kinase Inhibitor Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18275119 Inhibitors Of Protein Kinase A Patented View
18273360 Derivatives Of Imidazo[4,5-D]pyridazine, Their Preparation And Their Therapeutic Application Patented View
18002187 Novel Compounds Patented View
17607595 Inhibiting Usp36 Patented View
18253387 Crystalline Forms Of Quinazolinone Compound And Process For Preparing The Same Abandoned View
17820522 Compositions And Methods For Modulating Inflammatory And Degenerative Disorder Patented View
17610617 Compounds For Treating Huntington's Disease Patented View
17614815 Methods Of Treating Fibrosis Using Compounds That Promote Glucose Oxidation Patented View
17262358 Single Molecule Compounds Providing Multi-Target Inhibition Of Btk And Other Proteins And Methods Of Use Thereof Patented View
18261778 Hect E3 Ubiquitin Liagase Inhibitors And Uses Thereof Patented View
17913936 Use Of Agents For Treatment Of Respiratory Conditions Abandoned View
17928719 Treatment For The Inflammatory Bowel Disease Abandoned View
17784401 Irak Degraders And Uses Thereof Patented View
18285788 Ulk1/2 Inhibitors And Their Use Thereof Abandoned View
18024722 Process For Preparing A Tetrazole-Substituted Anthranilic Acid Diamide Derivative Patented View
17610276 Method And Composition For Treatment Of Skin Diseases Associated With Accelerated Corneodesmosomes Degradation Or Weaker Cell-Cell Adhesion Patented View
17798605 Use Of Pyrido[1,2-A]pyrimidinone Compound In Treating Lymphoma Abandoned View
18175252 Treatment Of Schizophrenia Using Beta-Caryophyllene And Cb2 Receptor Agonists Abandoned View
18252423 Crystal Forms Of 5-Fluoro-1-(4-Fluoro-3-(4-(Pyrimidin-2-Yl)piperazine-1-Carbonyl)benzyl)quinazoline-2,4(1h,3h)-Dione And Preparation Thereof Patented View
17921043 Substituted Aminothiazoles As Dgkzeta Inhibitors For Immune Activation Abandoned View
17768174 [1,4]oxazepino[2,3-C]quinolinone Derivatives As Bcl6 Inhibitors Patented View
17614053 Microbiocidal Derivatives Patented View
19018805 Compounds As Glp-1r Agonists Patented View
17619733 Composition For The Treatment Of Muscle Wasting Patented View
17639724 Pharmaceutical Formulations Comprising Diclofenac Abandoned View
17605206 8-Substituted Aryl Vinyl Xanthine Derivatives And Uses Thereof Abandoned View
17423432 Antimicrobial Compounds And Methods Patented View
17044757 Phospholipid-Flavagline Conjugates And Methods Of Using The Same For Targeted Cancer Therapy Patented View
17768429 Phospholipid-Flavagline Conjugates And Methods Of Using The Same For Targeted Cancer Therapy Patented View
17757699 Composition For Treating Synucleinopathies Abandoned View
17621457 Novel Compounds Abandoned View
18015997 Crystal Of Pyrimidine Compound Patented View
17664026 Pyrrolotriazine Compounds Acting As Mnk Inhibitor Patented View
17924863 Small Molecule Inhibitors Of Cav3.2 Activity And Uses Thereof Patented View
17756888 Muscarinic Receptor 4 Antagonists And Methods Of Use Patented View
16635217 Methods And Compositions For Treating Cancer Patented View
17997288 Substituted N-(Methyl-D3)pyridazine-3-Carboxamide Or N-(Methyl-D3)-Nicotinamide Compounds As Il-12, Il-23 And/or Ifnalpha Modulators Patented View
17917571 Composition For Cancer Prevention Or Treatment, Containing, As Active Ingredient, Salvianolic Acid B Or Tanshinone I Abandoned View
17433730 Compositions Including Cinnamic Acid And Methods Of Use Thereof Patented View
17381538 Organic Compound, Organic Photoelectric Device, Image Sensor, And Electronic Device Patented View
17611544 Treatment Of Fibrosis With Ire1 Small Molecule Inhibitors Patented View
16474487 Methods Of Treating Bacterial Infections Patented View
17769787 Methods For The Preparation Of 5-Bromo-2-(3-Chloro-Pyridin-2-Yl)-2h-Pyrazole-3-Carboxylic Acid Abandoned View
17919490 Quinoline Compounds And Compositions For Inhibiting Ezh2 Patented View
17433935 Methods Of Treating Trigeminal Nerve Pain Patented View
17905072 Compounds As Cdk2/4/6 Inhibitors Abandoned View
17782478 Solid Forms Of 2-((4-((S)-2-(5-Chloropyridin-2-Yl)-2-Methylbenzo[D][1,3]dioxol-4-Yl)piperidin-1-Yl)methyl)-1-(((S)-Oxetan-2-Yl)methyl)-1h-Benzo[D]imidazole-6-Carboxylic Acid, 1,3-Dihydroxy-2-(Hydroxymethyl)propan-2-Amine Salt Abandoned View
17610570 Compounds And Compositions For Treating Conditions Associated With Sting Activity Abandoned View
17984405 Pharmaceutical Compositions Of Spironolactone For Deep Dermal Drug Delivery Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.